Tall cell carcinoma with reversed polarity of breast cancer: a rare case report and review of the literature

Tall cell carcinoma with reversed polarity (TCCRP) is a primary invasive breast cancer that is clinicopathologically characterized by reversed polarity of the nucleus of the tumor cells near the cell edge. This pathologic feature is so rare that only 82 cases of TCCRP have been reported worldwide since it was first reported in 2003. Herein, we present the 83rd case of TCCRP. Going one step further than the previous reports, our case includes genetic testing. We sought to explore whether there are new mutation sites, with a view to identifying more therapeutic options for patients in future, to find PIK3CA p.H1047R mutation and IDH2 R172T mutation.We have found the macrophase makers CD68/CD163 double positive in this patient, which may indicate a poor prognosis in the early time. Therefore, the patient was treated with postoperative radiotherapy. The patient continues to be followed up for prognostic evaluation, and no recurrence or metastasis occurred until now. The case has represented a full view to gaining an improved understanding of TCCRP.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2025-11-03
DOI
https://doi.org/10.3389/fonc.2025.1635976
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tall cell carcinoma with reversed polarity of breast cancer: a rare case report and review of the literature

Longmei Zhang, Mingguang Ren, Junling Gao, Wenqi Duan et al.
Frontiers in Oncology
Advanced Breast Cancer Therapies
article

Tall cell carcinoma with reversed polarity of breast cancer: a rare case report and review of the literature

Longmei Zhang, Mingguang Ren, Junling Gao, Wenqi Duan, Jianing Jiang, Zhe Wang, Huajian Wu, Ya Deng, Guo Chunlong
article en

Abstract

Tall cell carcinoma with reversed polarity (TCCRP) is a primary invasive breast cancer that is clinicopathologically characterized by reversed polarity of the nucleus of the tumor cells near the cell edge. This pathologic feature is so rare that only 82 cases of TCCRP have been reported worldwide since it was first reported in 2003. Herein, we present the 83rd case of TCCRP. Going one step further than the previous reports, our case includes genetic testing. We sought to explore whether there are new mutation sites, with a view to identifying more therapeutic options for patients in future, to find PIK3CA p.H1047R mutation and IDH2 R172T mutation.We have found the macrophase makers CD68/CD163 double positive in this patient, which may indicate a poor prognosis in the early time. Therefore, the patient was treated with postoperative radiotherapy. The patient continues to be followed up for prognostic evaluation, and no recurrence or metastasis occurred until now. The case has represented a full view to gaining an improved understanding of TCCRP.

Frontiers in OncologyVol. 15
Dalian Medical University (CN), Second Affiliated Hospital of Dalian Medical University (CN), Affiliated Zhongshan Hospital of Dalian University (CN)
National Science Foundation, National Natural Science Foundation of China, Dalian Science and Technology Bureau, National Health Commission of the People's Republic of China
Openalex Percentile: Top 54%
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.